argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypes New biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and pipeline candidates empasiprubart and adimanebart at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago from April 18-22, 2026. “The data we will present at AAN, including new Phase 3 results in ocular myasthenia gravis, demonstrate our relentless efforts to deliver a targeted treatment option to as many patients living with MG as possible,” said Luc Truyen, M.D.

GlobeNewsWire • Mar 6, 2026

KMDA vs. ARGX: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Kamada (KMDA) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Mar 5, 2026

Baron Health Care Fund Q4 2025 Contributors And Detractors

Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing guidance for the next two quarters.

Seeking Alpha • Mar 3, 2026

These Analysts Revise Their Forecasts On Argenx After Q4 Earnings

Argenx SE (NASDAQ: ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).

Benzinga • Feb 27, 2026

Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades

For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but material correction in several holdings over the potential exposure of quality growth franchises to AI disruption. Lundin Mining Corporation shares rose meaningfully during the fourth quarter after the company raised its 2025 copper production outlook and lowered its cash cost guidance.

Seeking Alpha • Feb 27, 2026

argenx SE (ARGX) Q4 2025 Earnings Call Transcript

argenx SE (ARGX) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year ‑ over ‑ year growth

GlobeNewsWire • Feb 26, 2026

Argenx Touts Positive Phase 3 Eye Disease Study Results

Argenx SE (NASDAQ: ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).

Benzinga • Feb 26, 2026

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

Study met primary endpoint (p-value = 0.012) First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information  February 26, 2026, 6:30 AM CET     Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG). ADAPT OCULUS met its primary endpoint (p-value=0.012), showing that patients living with oMG and treated with VYVGART demonstrated statistically significant improvement from baseline in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores at Week 4 compared to placebo.

GlobeNewsWire • Feb 26, 2026

Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells

The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to performance for both the quarter and year. Management highlighted strong demand for high-speed optical components supporting AI-driven data center growth, alongside improving margins.

Seeking Alpha • Feb 26, 2026